Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma

American Journal of Neuroradiology

Volumn 32, Issue 7, 2011, Pages 1301-1306

  Gupta, A ^a   Young, Robert J ^a   Karimi, S ^a   Sood, S ^a   Zhang, Z ^a   Mo, Q ^a   Gutin, P H ^a   Holodny, A I ^a   Lassman, A B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; GADOLINIUM; IRINOTECAN; LOMUSTINE; TEMOZOLOMIDE;

ADULT; AGED; ANTIANGIOGENIC THERAPY; APPARENT DIFFUSION COEFFICIENT; ARTICLE; CAPSULA INTERNA; COMBINATION CHEMOTHERAPY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORONA RADIATA (BRAIN); CORPUS CALLOSUM; DIFFUSION WEIGHTED IMAGING; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PREDICTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; THALAMUS NUCLEUS;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 80052001722     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A2479     Document Type: Article

References (38)

1. Louis D.N., Ohgaki H., Wiestler O.D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109. Epub 2007 Jul 6
2. Castillo M., Smith J.K., Kwock L., et al. Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas. AJNR Am J Neuroradiol 2001;22:60-64 (Pubitemid 32105356)
3. Guo A.C., Cummings T.J., Dash R.C., et al. Lymphomas and high-grade astrocytomas: Comparison of water diffusibility and histologic characteristics. Radiology 2002;224:177-183 (Pubitemid 34680392)
4. Higano S., Yun X., Kumabe T., et al. Malignant astrocytic tumors: Clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006;241:839-846 (Pubitemid 46190551)
5. Saksena S., Jain R., Narang J., et al. Predicting survival in glioblastomas using diffusion tensor imaging metrics. J Magn Reson Imaging 2010;32:788-795
6. Murakami R., Sugahara T., Nakamura H., et al. Malignant supratentorial astrocytoma treated with postoperative radiation therapy: Prognostic value of pretreatment quantitative diffusion-weighted MR imaging. Radiology 2007;243:493-499 (Pubitemid 46649706)
7. Jain R., Scarpace L.M., Ellika S., et al. Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion-weighted imaging as an imaging biomarker. J Neurooncol 2010;96:423-431
8. Rieger J., Bahr O., Muller K., et al. Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol 2010;99:49-56
9. Mohile N.A., Abrey L.E. Assessment of treatment response to bevacizumab (bev) with MRI in recurrent malignant glioma (MG) [abstract MA-05]. Neuro Oncol 2007;9:516
10. Pope W.B., Kim H.J., Huo J., et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009;252:182-189
11. Gerstner E.R., Frosch M.P., Batchelor T.T. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 2010;28:e91-e93
12. Gerstner E.R., Chen P.J., Wen P.Y., et al. Infiltrative patterns of glioblastoma spread detected via diffusionMRIafter treatment with cediranib. Neuro Oncol 2010;12:466 -72. Epub 2010 Jan 22
13. Gutin P.H., Iwamoto F.M., Beal K., et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009;75:156-163
14. Larsson H.B., Tofts P.S. Measurement of Blood-brain barrier permeability using dynamic Gd-DTPA scanning: A comparison of methods. Magn Reson Med 1992;24:174-176
15. Law M., Oh S., Johnson G., et al. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: A second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery 2006;58:1099 -1107, discussion 1099-107
16. Young R.J., Knopp E.A. Brain MRI: Tumor evaluation. J Magn Reson Imaging 2006;24:709-724 (Pubitemid 44546983)
17. Al-Okaili R.N., Krejza J., Wang S., et al. Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors in adults. Radiographics 2006;26(suppl 1):S173-S189
18. Wetzel S.G., Cha S., Johnson G., et al. Relative cerebral blood volume measurements in intracranial mass lesions: Interobserver and intraobserver reproducibility study. Radiology 2002;224:797-803 (Pubitemid 34919816)
19. Wen P.Y., Macdonald D.R., Reardon D.A., et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-72. Epub 2010 Mar 15
20. Hormigo A., Gutin P.H., Rafii S. Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers. Cancer Cell 2007;11:6-8 (Pubitemid 46054523)
21. Sugahara T., Korogi Y., Kochi M., et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9:53-60 (Pubitemid 29068231)
22. Gupta R.K., Cloughesy T.F., Sinha U., et al. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 2000;50:215-226 (Pubitemid 32192873)
23. Gupta R.K., Sinha U., Cloughesy T.F., et al. Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma. Magn Reson Med 1999;41:2-7 (Pubitemid 29068028)
24. Bulakbasi N., Guvenc I., Onguru O., et al. The added value of the apparent diffusion coefficient calculation to magnetic resonance imaging in the differentiation and grading of malignant brain tumors. J Comput Assist Tomogr 2004;28:735-746 (Pubitemid 39489910)
25. Fan G.G., Deng Q.L., Wu Z.H., et al. Usefulness of diffusion/perfusion- weighted MRI in patients with non-enhancing supratentorial brain gliomas: A valuable tool to predict tumour grading? Br J Radiol 2006;79:652-58. Epub 2006 Apr 26
26. Kim H.S., Kim S.Y. A prospective study on the added value of pulsed arterial spin-labeling and apparent diffusion coefficients in the grading of gliomas. AJNR Am J Neuroradiol 2007;28:1693-1699 (Pubitemid 47598142)
27. Kitis O., Altay H., Calli C., et al. Minimum apparent diffusion coefficients in the evaluation of brain tumors. Eur J Radiol 2005;55:393-400 (Pubitemid 41215567)
28. Tozer D.J., Jager H.R., Danchaivijitr N., et al. Apparent diffusion coefficient histograms may predict low-grade glioma subtype. NMR Biomed 2007;20:49-57
29. Alvarez-Linera J., Benito-Leon J., Escribano J., et al. Predicting the histopathological grade of cerebral gliomas using high b value MR DW imaging at 3-Tesla. J Neuroimaging 2008;18:276-81. Epub 2008 May 5
30. Kleinschmidt-Demasters B.K., Damek D.M. The imaging and neuropathological effects of bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis. J Neurooncol 2010;96:375- 84. Epub 2009 Jul 16
31. Rees J.H., Smirniotopoulos J.G., Jones R.V., et al. Glioblastoma multiforme: Radiologic- pathologic correlation. Radiographics 1996;16:1413-1438, quiz 1462-63
32. Scherer H.J. The forms of growth in gliomas and their practical significance. Brain 1940;63:1-35
33. Krishnan A.P., Asher I.M., Davis D., et al. Evidence that MR diffusion tensor imaging (tractography) predicts the natural history of regional progression in patients irradiated conformally for primary brain tumors. Int J Radiat Oncol Biol Phys 2008;71:1553- 62. Epub 2008 Jun 4
34. Chen W., Delaloye S., Silverman D.H., et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol 2007;25:4714-4721 (Pubitemid 350086472)
35. Grommes C., Akhurst T.J., Blasberg R.G., et al. [18F]FACBC and [18F]FLT PET imaging for glioblastomas (GBM) [abstract]. Neurology 2010; 74 (Suppl 2): A594
36. Stupp R., Mason W.P., Van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996 (Pubitemid 40349501)
37. Brandes A.A., Tosoni A., Spagnolli F., et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology. Neuro Oncol 2008;10:361-367
38. Sasaki M., Yamada K., Watanabe Y., et al. Variability in absolute apparent diffusion coefficient values across different platforms may be substantial: a multivendor, multi-institutional comparison study. Radiology 2008;249:624-630